Cell Death and Disease,
Год журнала:
2023,
Номер
14(11)
Опубликована: Ноя. 1, 2023
Abstract
Pancreatic
ductal
adenocarcinoma
(PDAC)
is
a
highly
aggressive
cancer
most
frequently
detected
at
an
advanced
stage
that
limits
treatment
options
to
systemic
chemotherapy,
which
has
provided
only
marginal
positive
clinical
outcomes.
Currently,
the
first-line
chemotherapeutic
agent
for
PDAC
gemcitabine
(GEM).
However,
chemotherapy
resistance
GEM
often
overlooked
in
of
due
lack
effective
biological
markers.
Therefore,
it
crucial
find
new
prognostic
markers
and
therapeutic
targets
patients
with
PDAC.
In
this
study,
we
identified
novel
regulatory
mechanism
development
Here,
report
LINC01134
was
significantly
upregulated
primary
tumors
from
patients.
vitro
vivo
functional
studies
revealed
promotes
through
facilitating
stem
cell
features
modulating
cycle.
Mechanistically,
interactes
tumor
suppressor
miR-497-5p
cells.
Increased
downregulates
miR-140-3p
oncogenic
WNT5A
expression.
Moreover,
m
6
A
demethylase
FTO
participated
upregulation
by
maintaining
mRNA
stability
YTHDF2.
Taken
together,
present
study
suggested
FTO-mediated
stabilization
promote
miR-140-3p/WNT5A/WNT
pathway
Our
Frontiers in Pharmacology,
Год журнала:
2022,
Номер
12
Опубликована: Янв. 31, 2022
Hepatocellular
carcinoma
(HCC)
is
a
highly
mortal
cancer
that
could
be
treated
by
radiotherapy.
DNA
damage
response
(DDR)
vital
factor
affecting
development
after
Long
non-coding
RNAs
(lncRNAs)
have
been
revealed
to
regulate
and
repair
in
cells.
Nevertheless,
the
function
of
long
intergenic
non-protein
coding
RNA
1134
(LINC01134)
has
not
explored
DDR.
In
this
study,
we
targeted
digging
into
LINC01134
DDR
exploring
underlying
mechanism
HCC
RT-qPCR
was
employed
measure
expression,
found
significantly
upregulated
Functional
analysis
suggested
depletion
attenuated
radioresistance
cells
facilitating
damage.
vivo
assays
demonstrated
hindered
tumor
growth.
Mechanism
unveiled
sequestered
microRNA-342-3p
(miR-342-3p)
recruited
insulin-like
growth
2
mRNA
binding
protein
(IGF2BP2)
modulate
mitogen-activated
kinase
1
(MAPK1)
consequently
activating
MAPK
signaling
pathway.
Rescue
validated
LINC01134/miR-342-3p/MAPK1
axis
radio-resistant
conclusion,
might
identified
useful
biomarker
for
therapy
HCC.
Frontiers in Immunology,
Год журнала:
2022,
Номер
13
Опубликована: Апрель 28, 2022
Hepatocellular
carcinoma
(HCC)
is
a
common
malignancy
with
higher
mortality,
and
means
are
urgently
needed
to
improve
the
prognosis.
T
cell
exclusion
(TCE)
plays
pivotal
role
in
immune
evasion,
lncRNAs
represent
large
group
of
tumor
development
progression
modulators.
Using
TCGA
HCC
dataset
(n=374),
we
identified
2752
differentially
expressed
702
TCE-associated
lncRNAs,
which
336
were
both
groups.
As
using
univariate
Cox
regression
analysis,
those
associated
overall
survival
(OS)
subjected
LASSO-COX
analysis
develop
prognosis
signature.
The
model,
consisted
11
was
named
11LNCPS
for
11-lncRNA
signature,
validated
performed
better
than
two
previous
models.
In
addition
OS
TCE,
scores
had
significant
correlation
reduced
infiltrations
CD8+
cells
dendritic
(DCs)
decreased
Th1,
Th2,
pro
B
cells.
expected,
these
infiltration
alterations
significantly
worse
HCC.
Analysis
published
data
indicates
that
HCCs
transcriptomically
similar
responded
PDL1
inhibitor.
Of
LINC01134
AC116025.2
seem
more
crucial,
as
their
upregulations
affected
types’
OS,
compromised
responses
LncRNAs
impacted
many
cancer-associated
biological
processes
signaling
pathways,
particularly
involved
function
metabolism.
should
be
useful
predicting
Journal of Medicinal Chemistry,
Год журнала:
2023,
Номер
66(7), С. 4275 - 4293
Опубликована: Апрель 4, 2023
Chemotherapy,
targeted
therapy,
and
immunotherapy
are
effective
against
most
tumors,
but
drug
resistance
remains
a
barrier
to
successful
treatment.
Lysine-specific
demethylase
1
(LSD1),
member
of
histone
demethylation
modifications,
can
regulate
invasion,
metastasis,
apoptosis,
immune
escape
tumor
cells,
which
associated
with
tumorigenesis
progression.
Recent
studies
suggest
that
LSD1
ablation
regulates
resensitivity
cells
anticarcinogens
containing
checkpoint
inhibitors
(ICIs)
via
multiple
upstream
downstream
pathways.
In
this
review,
we
describe
the
recent
findings
about
biology
its
role
in
development
progression
cancer
resistance.
Further,
summarize
have
reversal
or
resensitive
effect
on
discuss
possibility
targeting
combination
other
agents
surmount
Carcinogenesis,
Год журнала:
2023,
Номер
44(6), С. 497 - 510
Опубликована: Май 5, 2023
Abstract
Lung
cancer
is
the
leading
cause
of
cancer-related
deaths
worldwide.
Epidermal
growth
factor
receptor
tyrosine
kinase
inhibitors
(EGFR-TKIs)
showed
great
therapeutic
efficacy
for
non-small
cell
lung
(NSCLC)
patients.
However,
acquired
resistance
severely
limits
clinical
application
and
EGFR-TKIs.
In
current
study,
we
found
that
solamargine
(SM),
a
natural
alkaloid
derived
from
fruit
Lycium
tomato
lobelia,
has
been
to
inhibit
progression
NSCLC
enhance
anticancer
effect
brief,
SM
significantly
inhibited
viability
cells
enhanced
gefitinib
(GFTN)
erlotinib
(ERL).
Mechanistically,
decreased
expression
MALAT1
induced
miR-141-3p,
whereas
reduced
SP1
protein
levels.
Interestingly,
both
Sp1
have
classical
conservative
binding
sites
miR-141-3p
in
their
3ʹ-UTR
regions.
Silence
overexpression
Sp1.
Subsequently,
promoter
activity
IGFBP1
were
upregulated
by
SM,
which
was
not
observed
with
overexpression.
Moreover,
inhibitory
on
blocked
knockdown
expression.
More
importantly,
combination
GFTN
synergistically
cancer.
Similar
results
experiments
vivo.
Finally,
relevance
MALAT1,
further
validated
using
bioinformatics
analysis.
Taken
together,
confirmed
EGFR-TKIs
regulating
MALAT1/miR-141-3p/Sp1/IGFBP1
signaling
pathway.
This
study
unravels
novel
mechanism
suggests
new
potential
NSCLC-associated
therapy.
Cell Death and Disease,
Год журнала:
2023,
Номер
14(11)
Опубликована: Ноя. 1, 2023
Abstract
Pancreatic
ductal
adenocarcinoma
(PDAC)
is
a
highly
aggressive
cancer
most
frequently
detected
at
an
advanced
stage
that
limits
treatment
options
to
systemic
chemotherapy,
which
has
provided
only
marginal
positive
clinical
outcomes.
Currently,
the
first-line
chemotherapeutic
agent
for
PDAC
gemcitabine
(GEM).
However,
chemotherapy
resistance
GEM
often
overlooked
in
of
due
lack
effective
biological
markers.
Therefore,
it
crucial
find
new
prognostic
markers
and
therapeutic
targets
patients
with
PDAC.
In
this
study,
we
identified
novel
regulatory
mechanism
development
Here,
report
LINC01134
was
significantly
upregulated
primary
tumors
from
patients.
vitro
vivo
functional
studies
revealed
promotes
through
facilitating
stem
cell
features
modulating
cycle.
Mechanistically,
interactes
tumor
suppressor
miR-497-5p
cells.
Increased
downregulates
miR-140-3p
oncogenic
WNT5A
expression.
Moreover,
m
6
A
demethylase
FTO
participated
upregulation
by
maintaining
mRNA
stability
YTHDF2.
Taken
together,
present
study
suggested
FTO-mediated
stabilization
promote
miR-140-3p/WNT5A/WNT
pathway
Our